Sage Therapeutics Inc - Company Profile
Powered by 
All the sales intelligence you need on Sage Therapeutics Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Sage Therapeutics Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Sage Therapeutics Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Sage Therapeutics Inc (Sage Therapeutics) is a clinical-stage biopharmaceutical company that discovers, develops and markets drugs for the treatment of central nervous system (CNS) disorders. The company develops novel chemical entities targeting central nervous system receptor systems, specifically GABA and NMDA. Its flagship product Zurzuvae (zuranolone) is a FDA approved intravenous (IV) formulation administered for the treatment of postpartum depression (PPD). The company collaborates with companies such as Biogen and Shionogi for commercialization and development efforts. The company operates in the US, Bermuda, Switzerland, Scotland, England, and Wales through its subsidiaries. Sage Therapeutics is headquartered in Cambridge, Massachusetts, the US.
Headquarters
United States of America
Address
55 Cambridge Parkway, Massachusetts, 02142
Website
www.sagerx.com
Telephone
1 617 2998380
No of Employees
353
Industry
Pharmaceuticals and Healthcare
Revenue (2024)
$41.2M
Sage Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Zurzuvae (zuranolone): Postpartum Depression | Patient Support | Zurzuvae |
| Pipeline | Patient Advocacy | |
| Neurodevelopment Disorders: | ||
| XYZ | ||
| XYZ | ||
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Ownership Changes | In July, the company was acquired by Supernus Pharmaceuticals, Inc, a pharmaceutical company. |
| 2025 | Others | In January, the company rejected Biogen's acquisition proposal valued at US$469 million. |
| 2023 | Regulatory Approval | In August, the company and Biogen announced the U.S. Food and Drug Administration approved ZURZUVAE (zuranolone) 50 mg for adults with postpartum depression (PPD). |
Competitor Comparison
| Key Parameters | Sage Therapeutics Inc | Amgen Inc | Jazz Pharmaceuticals Plc | Marinus Pharmaceuticals Inc | Applied Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Ireland | United States of America | United States of America |
| City | Cambridge | Thousand Oaks | Dublin | Radnor | New York City |
| State/Province | Massachusetts | California | Dublin | Pennsylvania | New York |
| No. of Employees | 353 | 31,500 | 2,890 | 165 | 28 |
| Entity Type | Private | Public | Public | Private | Private |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Geno Germano | Chairman | Executive Board | 2024 | 64 |
| Barry E. Greene | Chief Executive Officer; Director; President | Executive Board | 2020 | 61 |
| Christopher Benecchi | Chief Operating Officer | Senior Management | 2024 | 52 |
| Laura Gault, MD, Ph.D | Chief Medical Officer | Senior Management | 2022 | 56 |
| Michael Quirk, Ph.D. | Chief Scientific Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer